SCHEMBL2238856

SCHEMBL2238856

CC(c1ccccc1)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C19 P33261 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KCNA5 P22460 5/20 0.44
MEN1 O00255 1/20 0.44
TTR P02766 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 3/20 0.41
LMNA P02545 2/20 0.41
MAPK1 P28482 1/20 0.41
ADRA2A P08913 1/20 0.40
ADRA2C P18825 1/20 0.40
HIF1A Q16665 1/20 0.40
CYP1A2 P05177 1/20 0.39
KCNN4 O15554 1/20 0.39
SLC6A4 P31645 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
CHRM2 P08172 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13339074 1.00 ALDH1A1 (0.50) ALDH1A1CYP2D6CYP2C19HSD17B10KCNA5
SCHEMBL4489962 0.82 CYP2D6 (0.41) ALDH1A1CYP2D6CYP2C19HSD17B10KCNA5
SCHEMBL301345 0.80 ALDH1A1 (0.57) ALDH1A1CYP2D6CYP2C19HSD17B10KCNA5
SCHEMBL6021075 0.80 ALDH1A1 (0.57) ALDH1A1CYP2D6CYP2C19HSD17B10KCNA5
SCHEMBL28600445 0.80 CYP2D6 (0.42) ALDH1A1CYP2D6CYP2C19HSD17B10KMT2A
SCHEMBL17790421 0.79 KMT2A (0.48) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL28658365 0.79 HTT (0.40) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL8897023 0.78 ALDH1A1 (0.39) ALDH1A1CYP2D6CYP2C19HSD17B10KCNA5
SCHEMBL28354246 0.78 CRHBP (0.43) ALDH1A1CYP2D6CYP2C19HSD17B10KCNA5
SCHEMBL28024684 0.78 CYP2D6 (0.46) ALDH1A1CYP2D6CYP2C19HSD17B10KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4508101-B1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2026-03-25 EP disclosed
EP-4709518-A1 PROCESS FOR THE PREPARATION OF POLYISOBUTENE FROM OLEFINS FROM ISOBUTANOL OBTAINED FROM MIXED GUERBET REACTION OF ETHANOL AND METHANOL BASF SE (DE) 2026-03-18 EP disclosed
EP-4667447-A1 PROCESS FOR THE PREPARATION OF POLYISOBUTENE FROM BIO-BASED OLEFINS FROM PRIMARY ALCOHOL BASF SE (DE) 2025-12-24 EP disclosed
US-20250250382-A1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2025-08-07 US disclosed
US-20250250403-A1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2025-08-07 US disclosed
US-20250179224-A1 MEDIUM MOLECULAR POLYISOBUTENE WITH A CERTAIN DISTRIBUTION OF DOUBLE BOND ISOMERS BASF SE (DE) 2025-06-05 US disclosed
US-20250145742-A1 MEDIUM MOLECULAR POLYISOBUTENE WITH A HIGH CONTENT OF CERTAIN DOUBLE BOND ISOMERS BASF SE (DE) 2025-05-08 US disclosed
WO-2025082909-A1 PROCESS FOR IMPROVING THE STABILITY OF POLYISOBUTENES BASF SE (DE) 2025-04-24 WO disclosed
EP-4508100-A1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2025-02-19 EP disclosed
EP-4508101-A1 PROCESS FOR MANUFACTURING OF POLYISOBUTENE SUCCINIC ANHYDRIDES BASF SE (DE) 2025-02-19 EP disclosed
US-8349977-B2 Process for preparing high-reactivity isobutene homo- or copolymers BASF SE (DE) 2013-01-08 US disclosed
US-20120271058-A1 STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES SABROE THOMAS PETER (DK) 2012-10-25 US disclosed
US-20120165473-A1 PREPARATION OF DERIVATIVES OF ISOBUTENE COPOLYMERS BASF SE (DE) 2012-06-28 US disclosed
US-20120142868-A1 PREPARATION OF ISOBUTENE HOMO- OR COPOLYMER DERIVATIVES BASF SE (DE) 2012-06-07 US disclosed
US-20110201772-A1 PROCESS FOR PREPARING HIGH-REACTIVITY ISOBUTENE HOMO- OR COPOLYMERS BASF SE (DE) 2011-08-18 US disclosed
EP-1751170-A1 CHIRAL PHOSPHORUS COMPOUNDS UNIVERSITY COLLEGE DUBLIN (IE) 2007-02-14 EP disclosed
WO-2005118603-A1 CHIRAL PHOSPHORUS COMPOUNDS UNIVERSITY COLLEGE DUBLIN (IE) 2005-12-15 WO disclosed
US-5874436-A EFFECTIVE IN INHIBITING THE ACTION OF A BACTERIAL HISTIDINE PROTEIN KINASE; USEFUL AGAINST ANTIBIOTIC RESISTANT ORGANISMS DEMERS JAMES P (US) 1999-02-23 US disclosed
WO-1997048676-A1 TRIPHENYLALKYL ANTIMICROBIAL AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1997-12-24 WO disclosed
US-5643950-A INHIBITORS OF A BACTERIAL HISTIDINE PROTEIN KINASE ORTHO PHARMACEUTICAL CORPORATION (US) 1997-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120271058-A1 STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES CYP24A1, CYP2R1, VDR ALDH1A1 615/4885CYP2D6 202/4885CYP2C19 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.